"Uterine Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the UTERUS.
| Descriptor ID |
D014594
|
| MeSH Number(s) |
C04.588.945.418.948 C13.351.500.852.762 C13.351.937.418.875
|
| Concept/Terms |
Uterine Neoplasms- Uterine Neoplasms
- Neoplasms, Uterus
- Neoplasm, Uterus
- Uterus Neoplasm
- Uterus Neoplasms
- Neoplasms, Uterine
- Neoplasm, Uterine
- Uterine Neoplasm
Cancer of Uterus- Cancer of Uterus
- Uterus Cancers
- Cancer of the Uterus
- Uterus Cancer
- Cancer, Uterus
- Cancers, Uterus
- Uterine Cancer
- Cancer, Uterine
- Cancers, Uterine
- Uterine Cancers
|
Below are MeSH descriptors whose meaning is more general than "Uterine Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Uterine Neoplasms".
This graph shows the total number of publications written about "Uterine Neoplasms" by people in this website by year, and whether "Uterine Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 4 | 0 | 4 |
| 2006 | 7 | 0 | 7 |
| 2007 | 3 | 0 | 3 |
| 2008 | 3 | 0 | 3 |
| 2009 | 3 | 0 | 3 |
| 2010 | 4 | 2 | 6 |
| 2011 | 4 | 1 | 5 |
| 2012 | 4 | 1 | 5 |
| 2013 | 6 | 1 | 7 |
| 2014 | 6 | 0 | 6 |
| 2015 | 9 | 0 | 9 |
| 2016 | 9 | 4 | 13 |
| 2017 | 10 | 2 | 12 |
| 2018 | 13 | 1 | 14 |
| 2019 | 4 | 0 | 4 |
| 2020 | 15 | 0 | 15 |
| 2021 | 12 | 0 | 12 |
| 2022 | 17 | 0 | 17 |
| 2023 | 20 | 0 | 20 |
| 2024 | 11 | 1 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Uterine Neoplasms" by people in Profiles.
-
Uterine fibroids: current research on novel drug targets and innovative therapeutic strategies. Expert Opin Ther Targets. 2024 Aug; 28(8):669-687.
-
Surgical myomectomy followed by oral Myfembree vs standard of care (SOUL trial): Study protocol for a randomized control trial. PLoS One. 2024; 19(7):e0306053.
-
Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary. J Comp Eff Res. 2024 Aug; 13(8):e230194.
-
Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy. Cells. 2024 Jun 26; 13(13).
-
Altered extracellular matrix-related pathways accelerate the transition from normal to prefibroid myometrium in Black women. Am J Obstet Gynecol. 2024 Sep; 231(3):324.e1-324.e12.
-
Multiomic analysis of uterine leiomyomas in self-described Black and White women: molecular insights into health disparities. Am J Obstet Gynecol. 2024 Sep; 231(3):321.e1-321.e11.
-
Uterine Inflammatory Myofibroblastic Tumors: p16 as a Surrogate for CDKN2A Deletion and Predictor of Aggressive Behavior. Am J Surg Pathol. 2024 Jul 01; 48(7):813-824.
-
Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline. Int J Gynaecol Obstet. 2024 May; 165(2):431-441.
-
Empowering Strategies for Lifestyle Interventions, Diet Modifications, and Environmental Practices for Uterine Fibroid Prevention; Unveiling the LIFE UP Awareness. Nutrients. 2024 Mar 12; 16(6).
-
Management of Uterine Fibroids and Sarcomas: The Palermo Position Paper. Gynecol Obstet Invest. 2024; 89(2):73-86.